News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
Agilent Increases Cash Dividend to 23.6 Cents per Share
Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend. The quarterly
Value-Based Care Benefits Patients and Physicians, New Report Shows
Value-based care is smarter healthcare that lowers costs and keeps Medicare Advantage members healthier, according to the tenth annual Value-Based Care Report released today from Humana Inc. (NYSE
Tufts Medicine Selects Premier, Inc. as Strategic Partner to Achieve Supply Chain Excellence
Premier, Inc. (NASDAQ: PINC), a leading technology-enabled performance improvement company, today announced a renewed partnership with Tufts Medicine, a leading integrated health system bringing
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or
Simulations Plus Outlines Paths to Win at 2023 Investor Day
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today will host its investor
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin
Agilent Announces Thought Leader Award to Professor Jennifer Field
Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
EQS-News: Formycon publishes nine-month results for 2023
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients